Prognostic relevance of pulmonary arterial compliance after therapy initiation or escalation in patients with pulmonary arterial hypertension

International Journal of Cardiology

Volumn 230, Issue , 2017, Pages 53-58

  Ghio, Stefano ^a   D'Alto, Michele ^b   Badagliacca, Roberto ^c   Vitulo, Patrizio ^d   Argiento, Paola ^b   Mulè, Massimiliano ^e   Tuzzolino, Fabio ^d   Scelsi, Laura ^a   Romeo, Emanuele ^b   Raineri, Claudia ^a   Martino, Lavinia ^d   Tamburino, Corrado ^e   Poscia, Roberto ^c   Vizza, Carmine Dario ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

^e Ferrarotto Hospital   (Italy)

Author keywords

Prognosis; Pulmonary arterial hypertension; Right heart hemodynamics

Indexed keywords

ADULT; AGE; ARTERY COMPLIANCE; ARTICLE; COHORT ANALYSIS; DEATH; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GENDER; HEART CATHETERIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSTIC ASSESSMENT; PULMONARY ARTERY; PULMONARY HYPERTENSION; REPEAT PROCEDURE; SURVIVAL; SYSTEMIC SCLEROSIS; AGED; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; VASCULAR RESISTANCE;

AGED; CARDIAC CATHETERIZATION; COHORT STUDIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY ARTERY; ROC CURVE; VASCULAR RESISTANCE;

EID: 85009259812     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.12.099     Document Type: Article

References (31)

1. [1] D'Alonzo, G.E., Barst, R.J., Ayres, S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115 (1991), 343–349.
2. [2] McLaughlin, V.V., Shillington, A., Rich, S., Survival in primary hypertension—the impact of epoprostenol therapy. Circulation 106 (2002), 1477–1482.
3. [3] Sitbon, O., Humbert, M., Nunes, H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 40 (2002), 780–788.
4. [4] Humbert, M., Sitbon, O., Chaouat, A., et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122 (2010), 156–163.
5. [5] Humbert, M., Sitbon, O., Yaïci, A., et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur. Respir. J. 36 (2010), 549–555.
6. [6] Thenappan, T., Shah, S.J., Rich, S., Tian, L., Archer, S.L., Gomberg- Maitland, M., Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur. Respir. J. 35 (2010), 1079–1087.
7. [7] Benza, R.L., Miller, D.P., Gomberg-Maitland, M., et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122 (2010), 164–172.
8. [8] Nickel, N., Golpon, H., Greer, M., et al. The prognostic impact of follow up assessments in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 39 (2012), 589–596.
9. [9] Miller, W.L., Grill, D.E., Borlaug, B.A., Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction. J. Am. Coll. Cardiol. HF 1 (2013), 290–299.
10. [10] Dupont, M., Mullens, W., Skouri, H.N., et al. Prognostic role of pulmonary arterial capacitance in advanced heart failure. Circ. Heart Fail 5 (2012), 778–785.
11. [11] Pellegrini, P., Rossi, A., Pasotti, et al. Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure. Chest 145 (2014), 1064–1070.
12. [12] Al-Naamani, N., Preston, I.R., Paulus, J.K., Hill, N.S., Roberts, K.E., Pulmonary arterial capacitance is an important predictor of mortality in heart failure with a preserved ejection fraction. J. Am. Coll. Cardiol. HF 3 (2015), 467–474.
13. [13] Mahapatra, S., Nishimura, R.A., Sorajja, P., Cha, S., McGoon, M.D., Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J. Am. Coll. Cardiol. 47 (2006), 799–803.
14. [14] Galiè, N., Humbert, M., Vachiery, J.L., et al. ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 37 (2015), 67–119.
15. [15] McLaughlin, V.V., Gaine, S.P., Howard, L.S., Leuchte, H.H., Mathier, M.A., Mehta, S., Palazzini, M., Park, M.H., Tapson, V.F., Sitbon, O., J. Am. Coll. Cardiol. 62:25 Suppl (2013), D73–D81.
16. [16] Galiè, N., Manes, A., Negro, L., Palazzini, M., Bacchi-Reggiani, M.L., Branzi, A.A., Meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur. Heart J. 30 (2009), 394–403.
17. [17] McDonald's blood flow in arteries. Nichols, W.W., O'Rourke, M.F., (eds.) Theoretical, Experimental and Clinical Principles, fifth ed., 2005, Hodder Arnold, London.
18. [18] Wang, Z., Chesler, N.C., Pulmonary vascular wall stiffness: an important contributor to the increased right ventricular afterload with pulmonary hypertension. Pulm. Circ. 1 (2011), 212–223.
19. [19] Saouti, N., Westerhof, N., Helderman, F., et al. Right ventricular oscillatory power is a constant fraction of total power irrespective of pulmonary artery pressure. Am. J. Respir. Crit. Care Med. 182 (2010), 1315–1320.
20. [20] Campo, A., Mathai, S.C., Le Pavec, J., et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 182 (2010), 252–260.
21. [21] Gerges, C., Gerges, M., Skoro-Sajer, N., et al. Hemodynamic thresholds for precapillary pulmonary hypertension. Chest 149 (2016), 1061–1073.
22. [22] Sanz, J., Kariisa, M., Dellegrottaglie, S., et al. Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. J. Am. Coll. Cardiol. Img. 2 (2009), 286–295.
23. [23] Gan, C.T., Lankhaar, J.W., Westerhof, N., et al. Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary hypertension. Chest 132 (2007), 1906–1912.
24. [24] Douwes, J.M., Roofthooft, M.T., Bartelds, B., Talsma, M.D., Hillege, H.L., Berger, R.M., Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension. Int. J. Cardiol. 168 (2013), 1370–1377.
25. [25] Sajan, I., Manlhiot, C., Reyes, J., McCrindle, B.W., Humpl, T., Friedberg, M.K., Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival. Am. Heart J. 162 (2011), 562–568.
26. [26] Lankhaar, J.W., Westerhof, N., Faes, T.J., et al. Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension. Eur. Heart J. 29 (2008), 1688–1695.
27. [27] Savarese, G., Paolillo, S., Costanzo, P., et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J. Am. Coll. Cardiol. 60 (2012), 1192–1201.
28. [28] Ghio, S., Pica, S., Klersy, C., Guzzafame, E., Scelsi, L., Raineri, C., Turco, A., Schirinzi, S., Visconti, L.O., Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy. Open Heart, 3(1), 2016 May 9.
29. [29] Bonderman, D., Martischnig, A.M., Vonbank, K., et al. Right ventricular load at exercise is a cause of persistent exercise limitation in patients with normal resting pulmonary vascular resistance after pulmonary endarterectomy. Chest 139 (2011), 122–127.
30. [30] Ghio, S., Morsolini, M., Corsico, A., et al. Pulmonary arterial compliance and exercise capacity after pulmonary endarterectomy. Eur. Respir. J. 43 (2014), 1403–1409.
31. [31] Ahmad, T., Fiuzat, M., Pencina, M.J., et al. Charting a roadmap for heart failure biomarker studies. JACC Heart Fail 2 (2014), 477–488.